CTRP3 and Progranulin in Patients With Coronary Artery Disease
NCT ID: NCT01869816
Last Updated: 2020-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
362 participants
OBSERVATIONAL
2011-03-01
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
NCT02179047
Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis
NCT06337227
NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction
NCT06491667
Biomarkers for Cardiovascular Disease
NCT00109018
Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease
NCT05015270
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute coronary syndrome (ACS)
Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
No interventions assigned to this group
Stable angina pectoris (SAP)
Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
No interventions assigned to this group
Control
Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* unstable angina
* stable angina pectoris
Exclusion Criteria
* a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
* type 2 diabetes
* stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
* malignancy
* severe renal or hepatic disease
20 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyung Mook Choi
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung Mook Choi, M.D.
Role: PRINCIPAL_INVESTIGATOR
Korea University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital Dept. of Endocrinology
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAD(CTRP3,PRGL)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.